Baseline characteristics of trial populations
| . | Semaglutide 1.0 mg (n = 404) . | Exenatide ER 2.0 mg (n = 405) . | Total (n = 809) . |
|---|---|---|---|
| Age, years (min.–max.) | 56.4 (20–82) | 56.7 (21–83) | 56.6 (20–83) |
| HbA1c | |||
| % (min.–max.)* | 8.4 (6.7–11.1) | 8.3 (6.5–11.2) | 8.3 (6.5–11.2) |
| mmol/mol (min.–max.) | 67.9 (49.7–97.8) | 67.6 (47.5–98.9) | 67.7 (47.5–98.9) |
| Diabetes duration, years (min.–max.) | 9.0 (0.4–37.1) | 9.4 (0.3–54.0) | 9.2 (0.3–54.0) |
| Body weight, kg (min.–max.) | 96.2 (49.9–198.3) | 95.4 (53.2–171.9) | 95.8 (49.9–198.3) |
| BMI, (kg/m2) (min.–max.) | 34.0 (21.0–72.8) | 33.6 (21.2–55.8) | 33.8 (21.1–72.8) |
| eGFR (MDRD), mL/min/1.73 m2 (min.–max.) | 100.5 (60.0–208.0) | 100.5 (60.0–194.0) | 100.5 (60.0–208.0) |
| Sex, n (%) | |||
| Female | 185 (45.8) | 177 (43.7) | 362 (44.7) |
| Male | 219 (54.2) | 228 (56.3) | 447 (55.3) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 91 (22.5) | 106 (26.2) | 197 (24.4) |
| Not Hispanic or Latino | 313 (77.5) | 299 (73.8) | 612 (75.6) |
| Race, n (%) | |||
| White | 341 (84.4) | 338 (83.5) | 679 (83.9) |
| Black or African American | 28 (6.9) | 30 (7.4) | 58 (7.2) |
| Asian | 8 (2.0) | 6 (1.5) | 14 (1.7) |
| Other | 27 (6.6) | 31 (7.6) | 58 (7.2) |
| Diabetes medications at screening, n (%) | |||
| Biguanides | 391 (96.8) | 390 (96.3) | 781 (96.5) |
| Sulfonylureas | 181 (44.8) | 208 (51.4) | 389 (48.1) |
| Thiazolidinediones | 13 (3.2) | 6 (1.5) | 19 (2.3) |
| Other BG-lowering drugs (excluding insulin)† | 1 (0.2) | 2 (0.5) | 3 (0.4) |
| Long-acting insulins and analogs for injection† | 0 (0) | 1 (0.2) | 1 (0.1) |
| . | Semaglutide 1.0 mg (n = 404) . | Exenatide ER 2.0 mg (n = 405) . | Total (n = 809) . |
|---|---|---|---|
| Age, years (min.–max.) | 56.4 (20–82) | 56.7 (21–83) | 56.6 (20–83) |
| HbA1c | |||
| % (min.–max.)* | 8.4 (6.7–11.1) | 8.3 (6.5–11.2) | 8.3 (6.5–11.2) |
| mmol/mol (min.–max.) | 67.9 (49.7–97.8) | 67.6 (47.5–98.9) | 67.7 (47.5–98.9) |
| Diabetes duration, years (min.–max.) | 9.0 (0.4–37.1) | 9.4 (0.3–54.0) | 9.2 (0.3–54.0) |
| Body weight, kg (min.–max.) | 96.2 (49.9–198.3) | 95.4 (53.2–171.9) | 95.8 (49.9–198.3) |
| BMI, (kg/m2) (min.–max.) | 34.0 (21.0–72.8) | 33.6 (21.2–55.8) | 33.8 (21.1–72.8) |
| eGFR (MDRD), mL/min/1.73 m2 (min.–max.) | 100.5 (60.0–208.0) | 100.5 (60.0–194.0) | 100.5 (60.0–208.0) |
| Sex, n (%) | |||
| Female | 185 (45.8) | 177 (43.7) | 362 (44.7) |
| Male | 219 (54.2) | 228 (56.3) | 447 (55.3) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 91 (22.5) | 106 (26.2) | 197 (24.4) |
| Not Hispanic or Latino | 313 (77.5) | 299 (73.8) | 612 (75.6) |
| Race, n (%) | |||
| White | 341 (84.4) | 338 (83.5) | 679 (83.9) |
| Black or African American | 28 (6.9) | 30 (7.4) | 58 (7.2) |
| Asian | 8 (2.0) | 6 (1.5) | 14 (1.7) |
| Other | 27 (6.6) | 31 (7.6) | 58 (7.2) |
| Diabetes medications at screening, n (%) | |||
| Biguanides | 391 (96.8) | 390 (96.3) | 781 (96.5) |
| Sulfonylureas | 181 (44.8) | 208 (51.4) | 389 (48.1) |
| Thiazolidinediones | 13 (3.2) | 6 (1.5) | 19 (2.3) |
| Other BG-lowering drugs (excluding insulin)† | 1 (0.2) | 2 (0.5) | 3 (0.4) |
| Long-acting insulins and analogs for injection† | 0 (0) | 1 (0.2) | 1 (0.1) |
Values are arithmetic means (minimum–maximum) or n (%). eGFR, estimated glomerular filtration rate.
*Min./max. HbA1c may be outside the range specified in the inclusion criteria because measurements were taken at the randomization visit.
†Subjects receiving other BG-lowering drugs, insulins, and analogs for injection were randomized in error.